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ABSTRACT
Hurler syndrome (HS) is a severe inborn error of metabolism causing progressive multi-system morbidity and
death in early childhood. At present, stem cell transplantation (SCT) is the only available treatment that can pre-
vent central nervous systemdisease progression inHS patients. Although SCThas been shown to be effective for
several important clinical outcome parameters, the reported clinical outcome after successful SCT is variable
among HS patients and there are still some major limitations.
This review will focus on the clinical outcome of HS patients after successful SCT, with particular emphasis on
the long-term outcome and complications. In addition, factors that are suggested to contribute to the variable
outcome are outlined, as well as the limitations of SCT in HS patients.
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Hurler syndrome (HS) is a severe inborn error of
metabolism (IEM) causing progressive multi-system
morbidity, including developmental deterioration,
and death in early childhood. The first stem cell trans-
plantation (SCT) for HS was performed more than 25
years ago [1] and SCT is still the only treatment avail-
able that can prevent disease progression of the central
nervous system (CNS). Although SCT has been shown
to be effective for several important clinical outcome
parameters, the reported clinical outcome after suc-
cessful SCT is variable among HS patients and there
are still some major limitations. Although enzyme re-
placement therapy (ERT) has recently become avail-
able for Mucopolysaccharidosis type I (MPS I), this
treatment option is not indicated for HS patients be-
cause it is currently incapable of crossing the blood-
brain barrier (Figure 1).
This reviewwill focus on the long-term clinical out-
come of HS patients after successful SCT. In addition,
the progress that has been made in recent years will be
discussed. Furthermore, several factors that are sug-
gested to contribute to the variable outcome are dis-
cussed, as well as the limitations of SCT in HS patients.Hurler Syndrome
MPS I is a rare autosomal recessive IEM caused by
a deficiency of the lysosomal enzyme alpha-L-iduroni-
dase (IDUA). Historically, MPS I has been divided
into 3 clinical subtypes: Hurler (severe), Scheie
(mild/attenuated), and Hurler-Scheie (intermediate).
This classification is based on clinical factors, includ-
ing the age of onset, the rate of functional deteriora-
tion, and the range of affected organs (eg CNS
involvement). There are, however, no precisely de-
fined clinical or biochemical criteria that can reliably
distinguish among these subtypes [2,3]. It has been ac-
knowledged that these 3 subtypes represent a broad
continuous spectrum of clinical phenotypes, caused
by a high degree of genotype heterogeneity and associ-
ated with various degrees of residual enzyme activity
[2,4].
HS is themost severe phenotype in the spectrum of
MPS I, with incidence estimates varying between
1:76,000 and 1:164,000 [5,6]. The severely deficient,
or absent, IDUA enzyme activity inHS patients results
in a progressive accumulation of the incompletely
degraded glycosaminoglycans (GAGs) dermatan and
heparan sulphate within the lysosomes. Eventually,
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486 M. Aldenhoven et al.Figure 1. Enzyme delivery to the peripheral tissues and the central nervous system after stem cell transplantation.
In the peripheral tissues, the donormonocytes are able to cross the capillary wall, after which they differentiate into tissue-macrophages and secrete
the deficient enzyme for delivery to the various cells. In addition, these peripheral tissues will presumably also benefit from the freely circulating
enzymes, secreted by the donor leucocytes, because these enzymes are able to cross these capillary walls as well. Likewise, in enzyme replacement
therapy, the intravenously administered enzymes are able to cross the capillary wall of these peripheral tissues.
In the central nervous system (CNS), the donor monocytes cross the blood-brain barrier and differentiate into microglia. These ‘CNS macro-
phages’ deliver the deficient enzyme to the neurons and other cells in the CNS. As freely circulating enzymes in the bloodstream are not able
to cross the blood-brain barrier, the brains depend on these donor monocytes alone. This explains why enzyme replacement therapy is not ben-
eficial for the disease manifestations involving the CNS in contrast to a successful stem cell transplantation.widespread progressive cellular, tissue, and organ fail-
ure will originate, presenting clinically as progressive
and ultimately fatal multi-system deterioration [2].
The exact pathogenesis of the tissue and organ failure
in HS patients is still poorly understood. As the non-
degraded GAGs accumulate, the number, as well as
the volume, of the lysosomes increases, eventually
causing mechanical and chemical disruption of the
cell [7]. In addition to this direct (primary) effect of ac-
cumulating GAGs on cellular function, secondary
pathways are thought to be triggered as well, including
inflammatory processes (macrophage/cytokine re-
lease) [8] and the accumulation of GM2 andGM3 gan-
gliosides in the brain [9-11]. The clinical phenotype
and the detection of an increased amount of urinary
GAGs, showing predominant excretion of heparan
and dermatan sulphate, often suggest the diagnosis.
Definitive diagnosis of HS is confirmed by severely de-
creased or absent IDUA enzyme activity in peripheral
blood leukocytes, filter paper blood spots or fibro-
blasts, and subsequent mutation analysis [2,12].
Natural Course without StemCell Transplantation
HS patients usually have a normal appearance dur-
ing the first 6 months of life, although certain, mostly
non-specific, symptoms are often already present in
this initial period. These include mild facial dysmor-
phisms, persistent rhinitis, recurrent upper respiratory
tract infections, hepato-splenomegaly, recurrent her-
nias, and mild thoracolumbar kyphoscoliosis [13,14].After 6 months of age, HS patients will begin to de-
velop progressive multi-system morbidity including
progressive psychomotor retardation, impaired hear-
ing and vision, organomegaly, severe musculoskeletal
manifestations, and cardiovascular and pulmonary fail-
urewithdeath in early childhood [2]. Basedon anMPSI
registry, excluding patients with a known family his-
tory and prenatal diagnosis, diagnosis in HS patients
(n5137) was made at a median age of 10 mos (2-82
mos) with a median interval from symptom onset until
diagnosis of 4 mos (0-28 mos). This underscores the
difficulties of diagnosing patients with an evolving
phenotype [15].
STEM CELL TRANSPLANTATION IN HURLER SYNDROME
Frantantoni et al [16] were the first who demon-
strated the possibility of cross-correction of the defec-
tive metabolism in cultured fibroblasts derived from
Hurler and Hunter syndrome patients. A similar cor-
rection was subsequently shown in vivo by Di Ferrante
et al [17]. They demonstrated an induced degradation
of GAGs inHurler (andHunter) syndrome patients af-
ter the administration of normal human plasma. These
observations resulted in the first trial of SCT for HS,
reported in 1981 by Hobbs et al [1]. Biochemical im-
provement as well as a dramatic reversal of the clinical
manifestations in a 1 yr old boy with HS was demon-
strated and this case was a landmark ‘‘proof-of-princi-
ple’’ experiment.
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Following successful SCT, the donor-derived
stem cells provide a continuous endogenous source
of the deficient enzyme. The various peripheral tissues
(including the liver, spleen, lungs, and heart) presum-
ably benefit from both enzyme secretion by infiltrated
(donor) macrophages as well as enzymes secreted into
the bloodstream by (donor) leukocytes. Because freely
circulating enzymes are not able to cross the blood
brain barrier, the CNS relies on infiltration by macro-
phages alone. In the CNS, these macrophages differ-
entiate into microglia, which secrete the deficient
enzyme for recapture by the surrounding neurons
(Figure 1) [18].
Natural Course of Hurler Syndrome Patients after
Stem Cell Transplantation
Since the first bone marrow transplantation more
than 25 yrs ago [1], over 500 SCTs have been per-
formed in HS patients worldwide. Hence, SCT for
HS accounts for the majority (approximately 40%)
of SCTs performed in lysosomal storage disorders
[19,20]. After engraftment, significant improvement
in the clinical course of HS patients has been ob-
served, although there is wide variation among the
various tissues and organ systems, as well as among
HS patients. The outcome of the various tissues and
organ systems after SCT is discussed below, with par-
ticular emphasis on the long-term outcome (.3 yrs af-
ter SCT).
Biochemistry. Within 3 mos after successful SCT,
the leukocyte enzyme activity (IDUA), which is either
absent or severely decreased in untreated HS patients,
increases to values within the expected range of the do-
nor (heterozygote carrier or unaffected homozygote)
[21-26]. At the same time, the previously increased
GAG excretion is reduced to the upper limit of
age-matched control values, with a small amount of
dermatan sulphate and a hardly detectable fraction
of heparan sulphate at electrophoresis [21,24-26].
The obtained enzyme activity and GAG excretion re-
mained stable during long-term follow-up, provided
that donor chimerism remained stable [21-23;25-27].
Viscera. All untreatedHS patients suffer from hep-
ato-splenomegaly with preserved hepatic function [2].
In addition, a combination of respiratory manifesta-
tions is usually present. This includes a reduced lung
capacity, caused by interstitial pulmonary deposition
of GAGs and restricted diaphragmatic excursions, as
well as upper respiratory obstruction [28-30]. These
manifestations contribute to the severe obstructive
sleep apnea syndrome, commonly reported in
untreated HS patients [28,31]. In addition, recurrent
upper and lower respiratory tract infections often
occur [31]. Eventually, pulmonary hypertension and
cor pulmonale may develop, contributing to cardio-pulmonary failure and early death in untreated HS
patients [29].
In the cardiovascular system, left-sided cardiac
valve abnormalities (especially the mitral valve), pro-
gressive GAG deposition in the coronary arteries,
thoraco-abdominal aorta and systemic vessels with
subsequent stenosis, as well as primary myocardial in-
volvement are reported in untreated HS patients.
These manifestations will eventually evolve into a di-
lated cardiomyopathy with congestive heart failure,
largely contributing to the early death [3].
After successful engraftment, the metabolism and
clearance of GAGs is dramatically improved in the
highly perfused visceral organs, such as the liver,
spleen, adenoid, tonsils, heart, and lungs. A major re-
duction of the hepato-splenomegaly as well as relief
of the obstructive airway symptoms, including persis-
tent rhinorrhea and obstruction of the upper airways,
is seen in all patients within the first 3-6 mos after
SCT [21-22,25-26,32,33]. The occurrence of obstruc-
tive sleep apnea is markedly decreased after SCT and
pulmonary insufficiency is no longer observed, except
for those cases caused by transplantation-related pul-
monary complications [21,26,34-35]. Assessed by
echocardiography, myocardial function is preserved
and hypertrophy regressed after successful SCT and
remains so in long-term survivors [25,26,36-38].
Post-mortem examination of a 17 yr old HS patient
14 yrs after SCT showed only minimally affected cor-
onary arteries [39], which is in sharp contrast to the
progressive coronary artery disease observed in un-
treated children [40,41]. These improvements have
made death resulting from coronary occlusion or se-
vere congestive heart failure exceptionally uncommon
in HS patients after successful SCT [38]. In contrast to
these beneficial effects on the myocardium, long-term
follow-up revealed, however, that the mitral and aortic
valve deformities persisted and often progressed
[38,42]. Although valvular prolapse, insufficiency, or
stenosis did evolve in some cases, surgical intervention
was only rarely required. In addition, a case of persist-
ing coarctation of the aorta, probably because of pro-
gressive GAG deposition, has been reported in oneHS
patient, despite successful SCT [43].
Neurocognitive function. In untreated HS pa-
tients, normal cognitive and motor developmental
milestones are usually achieved until the age of 6
mos. Thereafter, psychomotor development slows
down, plateaus, and, eventually, progressive cognitive
and neurological deterioration takes place [3,44].
The pathophysiology of mental deterioration in HS
patients is not completely clarified. Both the primary
effect of accumulating GAGs on cellular function as
well as the secondary inhibition of ganglioside-degra-
dative lysosomal enzymes, causing accumulation of the
gangliosides GM2 and GM3 in the CNS, are thought
to play an important role [9]. This secondary
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topic dendritogenesis and cholesterol accumulation in
MPS mice, resulting in neuronal dysfunction [9].
Studies in transplanted MPS I dogs and cats
showed relative low levels of IDUA enzyme activity
in brain tissue and cerebrospinal fluid (CSF), com-
pared to the enzyme levels in the donor [45-47]. De-
spite these low enzyme levels, statistically significant
reductions in lysosomal GAG storage in brain tissue
and CSF of transplantedMPS I animals were reported,
compared to nontransplanted MPS I animals [45-47].
These GAG reductions were comparable to those
seen in the liver and the acquired GAG content in
the brain tissue and CSF appeared to be close to the
levels measured in the donors [45,47]. Additionally,
biochemical analysis demonstrated decreased CNS
ganglioside (GM2 andGM3) storage after transplanta-
tion [47]. Furthermore, histopathologic analysis
showed a clear therapeutic response in the meninges,
choroid plexus, and perivascular lesions, although the
improvement of the neuronal lesions appeared to be
only limited [45-48].
Long-term follow-up of HS patients after SCT
showed that when SCT is performed early enough in
the disease process, ie before extensive cerebral dam-
age has occurred, the neurocognitive development im-
proved or stabilized in most children, preventing
progressive mental deterioration. During longitudinal
evaluation, many patients have continued to gain skills,
although often at a slightly slower rate as compared to
unaffected children [21-23,25-27,49-51]. The neuro-
cognitive measurements in HS patients after SCT
are likely to be negatively affected by the associated
motor difficulties as well as the vision, hearing, and
speech impairment [22]. Furthermore, learning diffi-
culties, especially language problems, are frequently
reported later in the course of the disease, often caus-
ing special educational needs [21,22,25,27,50,51].
The neurocognitive outcome after SCT has been
shown to varywidely amongHSpatients.The variation
is theorized to depend on multiple factors, including
genotype, age at transplantation, cognitive situation
at transplantation, donor chimerism, donor status,
and enzyme activity after SCT [22,23,25,26,49,50].
The influence of these factors on the neurocognitive
outcome is discussed further in this article, although
the small study populations of current studies often
limit significancy.
Another CNS manifestation, which probably con-
tributes to neurocognitive dysfunction in untreated
HS patients, is communicating hydrocephalus. The
hydrocephalus is thought to be caused by a defective
reabsorption of CSF by the arachnoid villi as well as
thickened meninges, both resulting from GAG accu-
mulation [3,26,35]. After successful SCT, hydroceph-
alus is either prevented (when not present before
SCT) or stabilized, according to long-term follow-up; successfully engrafted patients no longer required
ventriculo-peritoneal shunting after transplantation
[21,22,25,26,33,51]. In addition to the hydrocephalus,
the progressive cerebral atrophy and massive accumu-
lation of GAGs in the Virchow-Robin spaces, which
can be demonstrated by magnetic resonance imaging
and computed tomography in all untreated HS pa-
tients, was arrested and subsequently reduced in sev-
eral patients after SCT [21,25,26,52].
In addition to the biochemical correction within
the brain and the prevention of elevated intracranial
pressure, the prevention of severe obstructive sleep ap-
neas, as well as improvements in visual acuity and hear-
ing, are thought to contribute to the preservation of
neurocognitive development in HS patients after
SCT as well [26,49].
Vision. The predominant ocular manifestation in
HS patients is progressive corneal clouding from der-
matan sulphate deposition in the cornea [53]. This is
associated with photophobia and causes a progressively
decreasing visual acuity in untreated patients. After
successful SCT, the reported outcome of corneal
clouding varies among HS patients, probably also
from difficulties in the objective grading of the corneal
opacities. Clinical improvement was seen in 20 to
100% of the patients, whereas only a few patients
showed progression of corneal clouding. Corneal
transplantation was therefore rarely required after
SCT [21,22]. However, in most patients mild residual
corneal clouding existed after SCT [1,32,54-56] and
long-term follow-up showed that this residual corneal
clouding persisted unchanged [21,22,26,27].
In addition to the corneal clouding, retinal degen-
eration is a commonly found ocular complication in
untreated HS patients and it contributes to the de-
creased visual acuity as well. Despite the stabilization
or improvement of the retinal function observed
soon after successful SCT [54], progressive retinal de-
generation did occur and it is likely to cause a decreased
visual acuity in the long-term survivors [55,57]. Optic
atrophy, caused by optic nerve edema secondary to el-
evated intracranial pressure, has been documented in
untreatedHS patients andmay contribute to visual im-
pairment as well [55,58]. Along with the increased in-
tracranial pressure, the optic nerve edema resolved
after successful SCT and atrophy was not longer ob-
served [55].
Hearing. In untreated HS patients, severe and pro-
gressive hearing loss, around 70 decibels or more, is
a universal problem. This is usually caused by a combi-
nation of conductive as well as neurosensory compo-
nents, including Eustachian tube dysfunction because
of GAGdepositions with subsequent otitismedia, dys-
ostosis of the auditory bones, damage resulting from
recurrent ear infections, and nerve damage [2,3,59].
After successful SCT, hearing is either gradually
normalized, improved, or stabilized in most HS
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proving conductive component, a late improvement
(5-6 yrs after SCT) of the neurosensory component
has been observed as well [25]. Only a small number
(0-20%) of successfully engrafted patients required
hearing aids [22,25,27]. In contrast, repeated grommet
insertions due to chronic recurrent middle ear infec-
tions are still commonly required after SCT [22,61].
Linear growth. Untreated HS patients suffer from
severe and progressive growth failure, achieving amax-
imal height of approximately 110 cm even when longer
survival is achieved [2]. This growth failure is charac-
terized by a disproportionately short trunk. After
SCT, linear growth is often maintained for several
years. However, long-term follow-up results (3-16
yrs post-SCT) showed that this growth gradually fell
to -1 standard deviation in most patients (67-71%)
and even below -2 standard deviations in several pa-
tients (29-40%; all .6 yrs post-SCT) [21;22;25].
This reduced linear growth could mainly be attributed
to a disproportionately short trunk, evidence by a re-
duced sitting height, independent of the presence or
absence of kyphoscoliosis [21,22,25]. In a recent study
using cord blood as a stem cell source, Staba et al [51]
documented normal growth velocities within 1 yr after
SCT in the majority of HS patients. These growth ve-
locities remained normal during their follow-up (max-
imum of 6 yrs after SCT). Longer follow-up is needed
to determine the effect of cord blood transplantation
on the linear growth of long-term survivors.
Skeletal outcome. Due to failure of ossification
and abnormal bonemodeling, several orthopedic com-
plications will progressively evolve in untreated HS
patients, leading to severe disability and discomfort.
These include thoraco-lumbar kyphosis resulting in
a typical gibbus deformity with subsequent spinal
cord compression; odontoid dysplasia at risk of devel-
oping cervical spine injury; acetabular dysplasia with
subsequent hip (sub)luxation; and genu valgum result-
ing in significant deformities [62]. In addition, carpal
tunnel syndrome (CTS) and associated trigger digits,
causing difficulties in fine motor tasks, are also fre-
quently reported in untreated HS patients [63,64].
Except for odontoid dysplasia, which showed pro-
gressive improvement after successful SCT [65,66],
increasing genu valgum, progressing acetabular dys-
plasia and the development of CTS were not pre-
vented by SCT, despite continued engraftment
[21,22,25,62,66]. In addition, HS patients often
showed progression of the thoracolumbar kyphosis,
although the rate of progression varied among pa-
tients [21,22,25,62,66]. As a consequence, orthopedic
and neurosurgical interventions were still necessary in
several HS patients after successful SCT, although
these interventions might have been postponed to
a later age. The fact that the musculoskeletal manifes-
tations can deteriorate after successful SCT is pre-sumably related to the relative avascularity of the
ground substance of the musculoskeletal tissues, pre-
cluding enzyme penetration into these tissues [62].
Although some authors were hopeful, speculating
that the musculoskeletal complications after SCT
were less severe or did progress less rapidly compared
to untreated patients [22,71], other authors were less
optimistic [62,67,72]. Careful systematic long-term
follow-up and documentation of orthopedic compli-
cations after SCT is warranted.
The patient’s age at transplantation might be an
important variable in the skeletal outcome after
SCT. Age at SCT was documented to significantly in-
fluence the age at the time of CTS surgery in HS pa-
tients (P5.007). In addition, there was a trend
towards increased time to onset of CTS in HS patients
with higher enzyme levels after SCT, although the co-
hort was too small to determine an absolute enzyme
level providing maximal benefit [71].
Joint mobility and functional performance.
Stiffness and contractures of the joints are very often
reported in untreated HS patients [2]. The restricted
joint mobility preferentially affects the hands, leading
to characteristic claw hand deformities [73], as well
as the shoulders. However, the typical restrictions of
these joints are often combined with a limited range
of motion in the elbows, wrists, hips, knees, ankles,
and/or spine [2].
After successful SCT, improvements in the upper
extremity joint mobility have been documented in
most HS patients [21,22,25,33,62,67]. Predominantly,
the shoulder and elbow movements showed a dramatic
improvement in range of motion measurements. The
development of clawing of the hands was limited com-
pared to untreated cases. Parental reports confirmed
these improvements, reporting increased daily activi-
ties that require upper extremity mobility [67]. These
improvements of the upper extremity joint mobility
were maintained during the follow-up of long-term
survivors (n544, ranging 3.2-15 yrs post-SCT)
[21,25,62,67]. Unfortunately, the lower extremities
showed a less successful outcome. A combination of
fixed flexion deformities of the lower limbs, progres-
sive hip (sub)luxation, limited hip abduction, genu val-
gum, and generalized muscle weakness did frequently
lead to a severely reduced walking ability or even com-
plete wheelchair dependency in long-term survivors
[22,27,62,69,74]. To maintain function and improve
the quality of life of the long-term survivors, a more ac-
tive approach to the expected orthopedic manifesta-
tions has been adopted, including intensive physical
therapy [62,75,76]. The benefits of early surgical inter-
vention, such as innominate osteotomy for hip dyspla-
sia, physeal stapling for genu valgum, and spinal fusion
for thoracolumbar kyphosis, for functional perfor-
mance in long-term survivors needs to be established
during longer follow-up [66,68,69].
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expectancy of HS patients after SCT has only recently
reached pubertal ages, little has been reported regard-
ing the sexual development of these patients.Vellodi et al
[22] reported primary ovarian failure with subsequent
delayed puberty in 2 of 5, and sexual infantilism in 1
of 5 pubertal age HS patients after SCT. The other
2 patients were thought to develop normally. The
ovarian failure was probably related to the chemother-
apy received before transplantation, although large
amounts of lysosomal storage have been observed in
the ovary of untreated female MPS I mice, consistent
with a reduced fertility [77]. There are, however, no
studies that have evaluated lysosomal storage in the
reproductive system of human patients. Pregnancy in
a 21-yr old female HS patient (severe genotype), 20
yrs after SCT, has been reported by Hendriksz et al
[78]. Due to concerns regarding her own health, she
decided to terminate the pregnancy.
Survival. Life expectancy has been significantly im-
proved after successful SCT [21,22,26,27,79]. This is
illustrated by survival, extending into the third decade
of life after successful SCT [1,27,80], compared to
a median survival of less than 5 years in untreated pa-
tients and only rare survivors beyond 10 years [2,79].
This greater lifespanofHSpatients after SCT ismainly
the result of the prevention of cardio-pulmonary com-
plications as well as the prevention of severe develop-
mental deterioration [38].
Factors influencing the Natural Course after Stem
Cell Transplantation
Interestingly, the natural course of clinical mani-
festations after successful SCT has been shown to be
highly variable among HS patients. This variability
has been suggested to depend on multifarious factors,
including:
Genotype. The gene coding for the IDUA en-
zyme, has been localized to chromosome 4 at location
4p16.3 [81]. At present, 95 disease-causing mutations
of the IDUA gene have been identified, including mis-
sense, nonsense, and splice site mutations, deletions,
and insertions [82].
Although genotype-phenotype correlations do not
always hold, the presence of a nonsense mutation on
both IDUA alleles causes severe HS in all cases [83].
These nonsense mutations are believed to result in
a complete lack of residual enzyme activity, causing
rapid accumulation of lysosomal GAG storage with
early onset of clinical signs and rapid disease progres-
sion. Two of these mutations, W402X and Q70X, are
particularly common in patients of European ancestry,
accounting for up to 70% of MPS I disease alleles, al-
though considerable differences in frequency are seen
across the various countries [84,85].
However, many patients have at least 1 private mu-
tation, restricted to a certain family pedigree, makingphenotype prediction difficult [86]. In addition,
many of the biochemical tests, used in a clinical setting
to diagnose IDUA enzyme deficiency, are not able to
discriminate between severe and intermediate pheno-
types; therefore, these tests are not helpful in predict-
ing the clinical phenotype.
Age at transplantation, neurocognitive devel-
opment at transplantation, and neurocognitive
outcome. Various reports have shown a favorable
and stable neurocognitive function in HS patients
with a relatively low risk of progressive cognitive dete-
rioration, but only when SCT is performed early in
life and before cerebral damage has occurred [21-
23,25,26,49,50]. Significant correlations, between the
age at SCT and the slope of the cognitive development
after SCT (-0.64; P\.03 and -0.51; P5.01), as well as
the baseline Mental Development Index (MDI) and
slope of the cognitive development after SCT (0.76;
P\.05 and 0.77; P5.0002), have been documented
in HS patients and support this finding [23,50].
Thus, both a younger age at SCT and a higher base-
line MDI are associated with better cognitive trajecto-
ries after SCT. Hence, some have suggested that SCT
should only be indicated in HS patients under the age
of 2 yrs and with no or only minimal cognitive impair-
ment (MDI .70). However, as the neurocognitive
outcome of HS patients older than 2 yrs at SCT or
with a baseline MDI below 70 did vary considerably
[22,23,49,50], these contraindications must be used
with caution [22,25]. The neurocognitive situation be-
fore SCT might be difficult to evaluate, especially in
younger patients or when hearing loss is present. In
addition, SCT might still be indicated after 2 yrs of
age in those patients who present with a slightly milder
phenotype. Therefore, it is important to realize that
a decision about SCT must be made on an individual
basis.
Donor status, donor chimerism, and enzyme
activity. A significantly higher leukocyte enzyme level
was accomplished in HS patients when an unaffected
homozygous donor was used and full donor chimerism
was achieved, compared to the situation where a het-
erozygous carrier donor was used or only mixed chi-
merism was achieved [21,23-26,87]. This higher
enzyme level after SCT was associated with a signifi-
cantly greater reduction of the urinary GAG excretion
in 39 HS patients, studied by Church et al [24], al-
though this latter effect was not observed in smaller se-
ries by other authors (in 15, 9, and 11 HS patients,
respectively) [21,25,26].
Donor status, donor chimerism, enzyme activ-
ity, and neurocognitive outcome. The question re-
mains whether the level of leukocyte enzyme activity
actually influences the long-term neurocognitive out-
come. Additionally, it is unknown whether this leuko-
cyte enzyme activity is a direct reflection of the enzyme
level delivered to the CNS.
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with enzyme levels of approximately 50% of normal,
are completely asymptomatic. In addition, patients
with the Scheie phenotype, presenting with only trace
amounts of residual IDUA enzyme activity, have an
attenuated clinical course without CNS deterioration.
Furthermore, a few HS patients with a confirmed
severe genotype were reported to have a normal neu-
rocognitive development (MDI .80) after SCT de-
spite of mixed donor chimerism or a heterozygous
donor and low enzyme levels [21,25,26,50,88]. The
acquired enzyme activity in most of these patients
was, however, still above 50% of normal. These
observations demonstrate that low enzyme levels,
although often at least in the heterozygous range,
are not necessarily associated with poor neurocogni-
tive outcome.
On the other hand, Peters et al [23] observed a cor-
relation between the donor enzyme status (homozy-
gous unaffected versus heterozygous carrier) and the
MDI at follow-up, in HS children with a baseline
MDI above 70. However, the children with homozy-
gous donors had a significantly higher baseline MDI
and were significantly younger at SCT. As both age
and MDI at SCT have been shown to be crucial for
the neurocognitive outcome after SCT, the correla-
tion between donor enzyme status and MDI at fol-
low-up is confounded [23]. In the same study, all
children who retained normal mental functioning
(MDI .80) at follow-up, received a homozygous do-
nor transplant and showed full donor chimerism with
normal enzyme activity, and not one child whose ac-
quired enzyme activity was low (from a heterozygous
carrier donor of mixed chimerism) showed normal
mental functioning [23]. Therefore, the enzyme level
still seems to be an important influencing factor. A
slightly lower neurocognitive score after SCT in HS
patients with subnormal enzyme levels was also seen
by Guffon et al [25] although the study population
was too small to draw conclusions.
Whether normal leukocyte enzyme activity,
achieved when using a homozygous unaffected donor
and with full donor chimerism, favorably contributes
to the cognitive development of HS patients should
be analyzed in future studies with larger study popula-
tions [23]. Nevertheless, we are aware that various pe-
diatric transplantation centers now prefer an unrelated
donor rather than a related family donor with a high a-
priori risk of being a carrier.
Stem cell source: cord blood. In various studies,
the use of cord blood (CB) as the stem cell source in
HS patients was associated with higher rates of suc-
cessful sustained engraftment, compared to bone mar-
row and peripheral blood (84-85% vs 26-75%) (Table
1) [21,23,50,51,89]. However, the results obtained
with SCTs using CBmainly involved SCTs performed
during the last decade, whereas many of the studies us-ing bone marrow (BM) or peripheral blood (PB) have
been accomplished over the last several decades.
Therefore, these higher rates of successful engraft-
ment in CB recipients might have been caused by other
factors, including changes in conditioning regimen.
This is supported by a recent retrospective European
group for Bone and Marrow Transplantation
(EBMT) study, analyzing risk factors for graft failure
in 146 HS patients. This study showed no significant
difference in engraftment between the use of CB,
BM and PB stem cells [87].
Although no difference in survival or graft failure
could be demonstrated between the recipients of the
various stem cell sources, the authors did show that
significantly more patients receiving a CB transplant
achieved full donor chimerism (93%), compared to
other stem cell sources (BM and PB, 66%: OR 9.31;
P5.044). Furthermore, all patients receiving a CB
transplant obtained normal enzyme levels, compared
to 60% in the other group [87]. Other studies that
used CB as a stem cell source, also showed high inci-
dences of full donor chimerism and normal enzyme
levels in HS patients (Table 1) [24,51,89,90], as well
as in other IEM [90-92]. Because full donor chimerism
and higher enzyme levels after SCT have been sug-
gested to positively influence the neurocognitive out-
come after SCT, CB might be a preferential stem
cell source for HS patients. Whether the stem cell
source could influence the long-term outcome, includ-
ing the neurocognitive development after SCT, should
be further clarified according to systematic long-term
follow-up.
Furthermore, the use of CB for SCT has several
other important advantages compared to other stem
cell sources (BM, PB), including: 1)Cord blood is read-
ily available (oftenwithin amonth), significantly reduc-
ing the time between diagnosis and SCT [51,91,93].
This is particularly important for the rapidly progres-
sive CNS involvement in HS patients; 2) Donors with
a larger number of human leukocyte antigen disparities
can be used, increasing the possibility of finding a suit-
able donor [51,94]; 3) Despite the higher level of hu-
man leukocyte antigen incompatibility, lower rates of
acute and chronic graft-versus-host disease (aGVHD,
cGVHD) are reported [51,90,94]; 4) The likelihood
of transmitting (viral) infections is reduced [94,95];
and 5) Although highly speculative, there are sugges-
tions of trans-differentiation into cell types such as os-
teoblasts, chondroblasts, and neurons, because of the
more primitive stem cell population in CB [96-98].
Disadvantages that are reported using CB as a stem
cell source are: 1) An increased aplasia duration, due to
the lesser amount of stem cells in CB; 2) The availabil-
ity of only one donation per donor; and 3) Less adop-
tive immunity, which might increase the likelihood of
life-threatening viral reactivations [93]. These disad-
vantages are, however, less applicable to HS patients.
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stem cells in order to obtain successful engraftment
(because of their low body weight) and as relatively
low graft failure rates are reported after the use of
CB, one CB donation is sufficient in most cases. Fur-
thermore, because of their young age, HS patients
have suffered from only limited viral infections before
SCT, considerably reducing the probability of devel-
oping viral reactivation.
Limitations of Stem Cell Transplantation in Hurler
Syndrome
Although SCTs in HS patients have clearly shown
to be effective, evident by an increased life expectancy
and improvement of various important clinical out-
come parameters, there are still some major limita-
tions, including:
Incomplete response. Successful engraftment
does not prevent disease progression in all organ sys-
tems and because the life expectancy of HS patients
has been increased, several severe disease manifesta-
tions have become apparent in long-term survivors.
Despite achieving successful engraftment, the follow-
ing conditions have been reported by various authors:
progression of retinal degeneration likely to result
in visual deficiency [55-57]; continued thickening of
cardiac valves leading to progressive valvular prolapse,
insufficiency, or stenosis [38,42]; and musculoskeletal
deterioration causing severe orthopedic complications
[21,22,25,27,62,66-70].
In addition, it was noticed that the neurocognitive
development continued to deteriorate during the
immediate post-transplantation period [51,99]. This
might be due to the delay in macrophage (microglia)
Table 1. Results of engraftment and enzyme activity after stem cell transplantation in Hurler syndrome patients
GvHD
n
Stem cell
source
Conditioning
regimen
Median age
at SCT
(mos)
Median
follow-up
(mos)
Successful
SCT1
(%)
Full donor
chimerism2
(%)
Normal
enzyme
level3
(%) Acute4 (%) Chronic5 (%)
Peters et al.
1996 [50]
21 BM6 48 20 34 43 87 56 30 30/18
19 BM7 49 26 67
Peters et al.
1998 [23]
28 BM10 412 22 88 75 71 30 32 0/0
26 BM11 413 23 55 35 89 0 55 41/23
Souillet et al.
2003 [21]
27 BM 414 25 72 70 52 53 9 0/0
Staba et al.
2004 [51]
20 CB Bu*Cy/ATG15 16 30 85 100 100 25 12/0
Boelens et al.
2007 [87]
146 416 417 18 44 56 71 60 16 7/2
Boelens et al.
2007 [89]
1518 CB 420 19 18 40 100 100 15 19/8
2519 421 84 9022 100
Ara-C indicates cytarabine; ATG, anti-thymocyte globulin; BM, bone marrow; Bu, busulphan; Bu*, busulphan (targeting), CB: Cord blood, Cy:
cyclophosphamide; Cy*, cyclophosphamide (high dose); Flud-Based, Fludurabine based myeloablative regimen; GVHD, Graft-versus-Host
Disease; n, number of patients; PB, peripheral blood; RIC, reduced intensity conditioning; SCT, stem cell transplantation; TBI, total body
irradiation; TLI, total lymphoid irradiation; VP-16, etoposide;4, various.
1alive and .10% donor chimerism
2% of patients with $95% donor chimerism from total number of successful transplanted patients
3% of patients with normal enzyme level (according to local reference values) from total number of successful transplanted patients
4% of grade II-IV (moderate to severe) acute GVHD
5% of total chronic GVHD / % of total extensive chronic GVHD
6High dose of BM ($3.5*108 cells/kg)
7low dose of BM (\3.5*108 cells/kg)
8Bu/Cy (12), VP-16/Cy/Ara-C/TBI (3), Cy/Ara-C/TBI (2), Bu/Cy/ATG (4)
9Bu/Cy (8), VP-16/Cy/Ara-C/TBI (1), Cy/Ara-C/TBI (4), Bu/Cy/ATG (1), Bu/Cy/TLI (2), 0,5Bu/0,5Cy/TBI (3)
10HLA-genotypically identical siblings
11HLA-haploidentical related donors
12Bu/Cy (23), Bu/Cy/TBI (1), Cy/TBI (1), Bu/Cy/TBI (1), ? (2)
13Bu/Cy (8), Ara-C/Cy/TBI (12), Cy/TBI (3), Bu/Cy/TBI (1), VP-16/Ara-C/Cy/TBI (1), ? (1)
14Bu/Cy (11), Bu/Cy/ATG (5), Bu/TBI (1), Bu*/Cy/ATG (10)
15Bu*/Cy/ATG (20)
16BM, PB, or CB
17Bu/Cy (68), Bu/Cy* (30), Bu* (15), Flud-based (17), RIC (18)
18SCTs\ 2001
19SCTs $ 2001
20Myeloablative (14), RIC (1)
21Myeloablative (24), RIC (1)
22n52 patients with mixed chimerism; 90% and 94%, still increasing
Outcome of Hurler Syndrome after Stem Cell Transplantation 493repopulation in the CNS, compared to other tissues.
Donor CNS microglial engraftment in mice was dem-
onstrated to be only 23% at 6 mos and 30% by 1 yr
post-SCT, compared to nearly 90% splenic macro-
phage engraftment by 1 mo and 98% by 6 mos [100].
Although it is not clear what level of microglial en-
graftment is required to arrest CNS disease progres-
sion in HS patients, the significantly slower rate of
CNS microglia repopulation (especially at parenchy-
mal sites [100]) might account for the disease progres-
sion in the immediate post-transplantation period
[8,100].
Furthermore, many of the complications associ-
ated withHS appeared to be irreversible, leading to re-
sidual disease, including mild corneal clouding
[1,32,54-56] and variable neurocognitive dysfunction
[21-23,25-27,49-51]. It should be clear that, in order
to improve the outcome of HS patients after SCT,
the SCT has to be performed as early as possible in
the course of the disease; before the onset of irrevers-
ible tissue damage has occurred.
Morbidity, mortality, and graft failure. Other
important limiting factors for the success of SCTs in
HS patients are treatment related morbidity and mor-
tality (TRM) [21,23,50,51,87]. The most frequent
occurring transplantation-related complications are
aGVHD and/or cGVHD, pulmonary complications
(hemorrhages and infections), and (mainly viral)
infections and reactivations. Survival rates of HS
patients after SCT vary between 50% and 85%
[21,23,50,51,87,89]. In addition to morbidity and mor-
tality, graft failure is also frequently reported in HS pa-
tients, resulting in relative low ‘alive and engraftment’
rates, varying between 34% and 85% after first SCT
[21-23,50,51,79,87,89]. In a retrospective EBMT
study, risk factors for graft failure in HS patients
(n5146) were identified. T cell depletion (P5.02) and
reduced-intensity conditioning (RIC, P5.002) were
found to be risk factors, while busulphan targeting pro-
tected against graft failure (P5.028). The results of this
study have resulted in novel EBMT-guidelines for SCT
in HS patients [101]. These observations might explain
why the more recent studies, using protocols according
to the novel EBMT-guidelines, showed better results in
terms of higher ‘alive and engraftment’ rates
[21,51,87,90].
OTHER TREATMENT OPTIONS
Enzyme replacement therapy
Since 2003, ERT has become commercially avail-
able for MPS type I patients. Recombinant human
IDUA (laronidase) has shown to give major clinical
improvements in patients with an attenuated form of
MPS type I (Scheie and Hurler-Scheie) and for these
patients ERT is the treatment of choice [3,102-104].
However, as the freely circulating enzymes, admin-istered during ERT, are not capable of crossing the
blood-brain barrier, this therapy is not effective in pre-
venting or treating the neurological signs and symp-
toms (Figure 1). ERT is therefore not indicated for
those patients suffering from a disorder with CNS in-
volvement, including HS patients.
In an attempt to improve their quality of life, ERT
has been used in transplant naı¨ve HS patients, al-
though only in small series [105-107]. The reasons to
use ERT instead of SCT in these patients were: a de-
layed diagnosis; significant developmental delay at di-
agnosis; lack of a compatible SCT donor; and major
concerns of parents about the risk of transplant-related
complications. Although various clinical benefits were
reported, not all affected tissues and organs did im-
prove [105,106]. Interestingly, an increase in cognitive
function at a normal rate in the patients who started
ERT at a younger age (\2.5 yrs) was reported during
a 1-yr treatment period by Wraith et al [105]. How-
ever, some of the developmental gains that were ob-
served during this study could be related to the
improvement in overall health status, including the
prevention of severe obstructive sleep apnea and im-
provement of visual activity and hearing [26,49], and,
in addition, follow-up was rather short. Long-term
follow-up, after 3 yrs of ERT, was reported in only 1
HS patient, started with ERT at 5 yrs of age. This pa-
tient showed a continued decline is respiratory status,
musculoskeletal involvement as well as developmental
skills [107].
The combination of ERT and SCT has been
evaluated in only a limited number of studies. The out-
come of 7 HS patients receiving ERT in combination
with SCTwas reported byTolar et al [108]; a larger se-
ries of 22 HS patients receiving ERT and SCT was
compared to a historic cohort in a multicenter study
by Cox-Brinkman et al [109]. In both studies, ERT
was started after confirmation of the diagnosis and its
administration was continued until successful engraft-
ment was achieved. Although ERT was well tolerated
in both studies, also previously shown by Grewal et al
[110], the combination of ERT and SCT did not sig-
nificantly influence the ‘alive and engraftment’ rate,
nor did it influence the SCT-associated morbidity
rate in the study of Cox-Brinkman et al [109]. There-
fore, these authors concluded that only for HS patients
in a poor clinical condition, making them ineligible for
SCT, ERT is indicated and only when one expects that
ERT can improve the clinical condition in a short pe-
riod of time. In HS patients in a moderate/good clini-
cal condition, early diagnosis and subsequent timely
SCT were considered to be more important than the
use of ERT prior to SCT [109]. Tolar et al [108], on
the other hand, reported a high survival rate and ac-
ceptable morbidity after the use of ERT in combina-
tion with SCT, despite the fact these patients were at
risk for pulmonary complications. Although based on
494 M. Aldenhoven et al.a small study population, they recommended ERT in
the pre-transplantation period in all severeHS patients
in order to improve morbidity and mortality. It is
evident that further research in this area is warranted
before a definitive statement can be made on the use
of ERT in SCT procedures.
Mesenchymal Stromal Cell Therapy
Mesenchymal stromal cells (MSCs) are non-hema-
topoietic pluripotent stem cells with the potential to
differentiate into various cells of mesenchymal origin
(eg osteoblasts, chondrocytes, and astrocytes). These
MSCs could therefore be valuable for HS patients, im-
proving or preventing some of the residual disease, in-
cluding the musculoskeletal and neurocognitive
manifestations.
Although BM contains both hematopoietic and
non-hematopoietic progenitors, Koc et al [111] were
the first to demonstrate that allogeneic bone marrow
transplantations in HS patients do not result in the
replacement of the non-hematopoietic progenitors,
including MSCs. This could have been caused by the
small number of non-hematopoietic progenitors in
the BM. Therefore, some years later, Koc et al [112]
infused MSCs, isolated and expanded from the bone
marrow of the original donor, in HS (and meta-
chromatic leukodystrophy) patients (n55 and n56,
respectively) who were successfully engrafted. Al-
though the procedure appeared to be safe and the
bone mineral density was either maintained or slightly
improved in all patients, there was no change in the
overall health and no detectable influence on the neu-
rocognitive and physical development of HS patients.
Therefore, further studies are needed to evaluate the
potential role of MSCs in the management of HS
patients.
Gene Therapy
Gene therapy represents a potential alternative
therapy by supplying a functional copy of the gene.
This could result in a constant delivery of the missing
enzyme to all tissues and organs or to targeted organs,
for example the musculoskeletal system or CNS [113].
Although gene therapy performed in MPS I animal
models did seem encouraging, further research is
needed before it could be clinically useful for HS pa-
tients [113,114].
NEONATAL SCREENING
The achievement of an optimal clinical outcome in
HSpatients after successful SCT, especially a favorable
neurocognitive outcome, has been shown to depend on
the age at transplantation [23,49,50]. Hence, early di-
agnosis as well as subsequent timely SCT, ideally be-
fore the onset of irreversible pathology, has become
highly important for a successful outcome. Becauseunrelated CB is suggested as a preferential stem cell
source and this source is readily available, timely trans-
plantation shortly after diagnosis has become possible.
In addition, early detection of HS, ideally in the pre-
symptomatic stage, could be made possible by imple-
menting a neonatal screening program. In addition
to a better outcome of clinical manifestations after
early SCT, there are several other advantages of early
diagnosis effected by neonatal screening in HS pa-
tients, including: 1) a higher rate of success with less
TRM when SCT is performed in the neonatal period
[91]. This is probably due to reduced organ damage
pre-SCT and fewer cases of viral reactivations after
transplantation; 2) The possibility of genetic counsel-
ing for the parents of an affected child, to provide the
option of prenatal diagnosis or pre-implantation ge-
netic diagnosis for subsequent pregnancies; and 3)
Avoidance of the prolonged and stressful process of di-
agnosis [115]. Possible disadvantages of neonatal
screening for HS include: 1) The costs of a neonatal
screening program; and 2) The false positive findings
that could generate anxiety in parents [115]. However,
because early diagnosis and subsequent early SCT
appear to be associated with a better clinical outcome,
the overall healthcare costs of HS patients could po-
tentially be decreased, reducing the overall financial
burden. Furthermore, since lysosomal storage disor-
ders have a combined incidence of around 1:7700
(even up to 1:5000 when all lysosomal storage disor-
ders are considered) [116], (which is twice as prevalent
as phenylketonuria), the simultaneous detection of
multiple, treatable lysosomal storage disorders com-
bined in one neonatal screening method could be eco-
nomically feasible.
Although it is already technically possible to diag-
nose HS using dried blood spots [12,117,118], demon-
stration of a significant medical benefit due to early
diagnosis is mandatory before such a newborn screen-
ing forHS can be implemented [119]. Tomeet this cri-
terion, an international observational study evaluating
the long-term outcome after successful SCT inHS pa-
tients, including the influence of early diagnosis, has
been initiated.
CONCLUSION
SCT is the preferred treatment forHS patients and
the long-term outcome of clinical manifestations in
HS patients after successful SCT appears to be prom-
ising. There are, however, some major limitations,
including high graft failure and TRM and morbidity
rates, although the more recent studies show better
results. Furthermore, some clinical manifestations
appear to be irreversible or continue to progress de-
spite successful SCT, causing residual disease burden
in long-term survivors. Interestingly, the long-term
Outcome of Hurler Syndrome after Stem Cell Transplantation 495clinical outcome appears to be highly variable among
HS patients, presumably caused by various factors.
Genotype, age at SCT, clinical situation at SCT,
donor status, donor chimerism, stem cell source, and
enzyme activity have all been suggested to influence
the long-term outcome, although this conclusion was
based primarily on small study populations. Unfortu-
nately, standardized long-term follow-up studies per-
formed in HS patients are lacking to confirm these
suggestions. To evaluate the natural course and the in-
fluence of various patient and donor characteristics on
the long-term outcome of HS patients after successful
SCT, an international long-term follow-up study has
been proposed and initiated, recently.
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